 |
0 Diseases |  |
30 Trials |
|
30 Trials |  |
224 News |  |
| 12345» |
- Tevimbra (tislelizumab-jsgr) / BeiGene
Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023. (Level 1, West Hall; Poster Bd #: F15) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_313;
P1/2
Clinical Trial Registration Number: NCT05319639. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- |||||| Rybrevant (amivantamab-vmjw) / J&J
Enrollment open, Trial completion date, Metastases: OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (clinicaltrials.gov) - Dec 10, 2024
P3, N=1000, Recruiting, Sponsor: Janssen Research & Development, LLC
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC Not yet recruiting --> Recruiting | Trial completion date: Jan 2032 --> Dec 2032
- | Opdivo (nivolumab) / BMS, BMS-986310 / BMS
Trial completion date: ONO-4578-04: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 25, 2024
P1, N=46, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
Not yet recruiting --> Recruiting | Trial completion date: Jan 2032 --> Dec 2032 Trial completion date: Nov 2024 --> Mar 2025
- ||| Avastin (bevacizumab) / Roche
P3 data, Journal, Metastases: Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). (Pubmed Central) - Nov 16, 2024
No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial primary completion date: EPOC2001: An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer (clinicaltrials.gov) - Nov 15, 2024
P2, N=43, Active, not recruiting, Sponsor: National Cancer Center Hospital East
FP + BEV is recommended for this population. Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Aug 2026
- | Opdivo (nivolumab) / BMS, magrolimab (ONO-7913) / Ono Pharma
Trial completion date, Trial primary completion date: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 14, 2024
P1, N=32, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Aug 2026 Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
- |||||||||| Rybrevant (amivantamab-vmjw) / J&J
New P3 trial, Metastases: OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (clinicaltrials.gov) - Oct 29, 2024
P3, N=1000, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: RAS mutant transverse colon cancer with multiple liver metastases achieving long-term disease-free survival with postoperative maintenance therapy with aflibercept?+?FOLFIRI and four repeated radical resections: a case report. (Pubmed Central) - Oct 8, 2024
We believe that multidisciplinary treatment aimed at complete resection could lead to long-term survival even in patients with repeated recurrence of CRLMs. Aflibercept?+?FOLFIRI could be effective in controlling metastasis of RAS mutant colon cancer even after treatment with bevacizumab.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal, Real-world evidence, Real-world, Metastases: A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group. (Pubmed Central) - Oct 7, 2024
The regimens with >20-fold cost of conventional chemotherapy were used as first-line chemotherapy in two-thirds of patients and more than half even in the elderly population with HER2-negative AGC. This finding is important for future health economic studies on drug cost-efficacy.
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial primary completion date, Metastases: NuTide:303: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Sep 26, 2024
P1/2, N=91, Recruiting, Sponsor: NuCana plc
This finding is important for future health economic studies on drug cost-efficacy. Trial primary completion date: Aug 2024 --> Jan 2025
- || NP137 / NETRIS Pharma
Trial completion date, Trial primary completion date, Metastases: LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Sep 21, 2024
P1, N=52, Recruiting, Sponsor: University Hospital, Grenoble
Trial primary completion date: Aug 2024 --> Jan 2025 Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026
- || Opdivo (nivolumab) / BMS, magrolimab (ONO-7913) / Ono Pharma
Trial completion date, Trial primary completion date: ONO-7913-04: The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2024
P1, N=65, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026 Trial completion date: Jan 2025 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Dec 2027
- | Journal, Combination therapy, Metastases: Early tumor shrinkage as a prognostic predictor in chemotherapy-na (Pubmed Central) - Sep 7, 2024
Trial completion date: Jan 2025 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Dec 2027 ETS may be a prognostic predictor in chemotherapy-na
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial completion date, Trial termination, Combination therapy, Metastases: NuTide:323: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) - Sep 2, 2024
P2, N=182, Terminated, Sponsor: NuCana plc
Trial completion date: Mar 2025 --> Aug 2024 | Active, not recruiting --> Terminated; A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: KEYMAKER-06C: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov) - Aug 23, 2024
P1/2, N=130, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Based on the Steering Committee's recommendation, the Sponsor has closed the study. Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS, BMS-986310 / BMS
New P1 trial: Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer (clinicaltrials.gov) - Aug 9, 2024
P1, N=40, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Metastases: Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Aug 9, 2024
P2, N=41, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| Opdivo (nivolumab) / BMS, magrolimab (ONO-7913) / Ono Pharma
New P1 trial: ONO-7913-04: The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer (clinicaltrials.gov) - Aug 6, 2024
P1, N=65, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- || Opdivo (nivolumab) / BMS, BMS-986310 / BMS
New P1 trial: ONO-4578-04: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 5, 2024
P1, N=46, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- || Opdivo (nivolumab) / BMS, magrolimab (ONO-7913) / Ono Pharma
New P1 trial: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 1, 2024
P1, N=32, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- | Khapzory (levoleucovorin) / Aurobindo
Preclinical, Journal: In vitro compatibility of admixture solutions of 5-fluorouracil and khapzory (disodium levofolinate) in a single infusion bag. (Pubmed Central) - Jul 27, 2024
Combining 5-FU and disodium levoleucovorin in admixture IV bags eliminates the risk of catheter occlusion associated with calcium-based levoleucovorin formulations. This approach offers a more favorable operational and safety profile, enhancing convenience for patients and cost-efficiency for institutions.
- ||||| Braftovi (encorafenib) / Pfizer
Enrollment closed, Metastases: BREAKWATER: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 9, 2024
P3, N=816, Active, not recruiting, Sponsor: Pfizer
This approach offers a more favorable operational and safety profile, enhancing convenience for patients and cost-efficiency for institutions. Recruiting --> Active, not recruiting
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Phase classification, Monotherapy: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov) - Jun 26, 2024
P1/2, N=130, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2
- |||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: KEYMAKER-06C: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov) - Jun 23, 2024
P1/2, N=130, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P1/2 trial, New P2 trial, Monotherapy: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov) - May 24, 2024
P2, N=130, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- | levoleucovorin calcium / Generic mfg.
Journal: Levoleucovorin inhibits LOXL2 (lysyl oxidase like-2) to control breast cancer proliferation: a repurposing approach. (Pubmed Central) - May 19, 2024
Levoleucovorin controlled cell proliferations in MDM-MB 231 and MCF-7 cells with GI50 values of 55.91 ?M and 79.20 ?M respectively. Further, a dose dependent inhibition of cancer cell migration was noted along with apoptosis induction in these cells with levoleucovorin treatment.Communicated by Ramaswamy H. Sarma.
- || Tyvyt (sintilimab) / Innovent Biologics
P2 data, Journal, Combination therapy, Metastases: Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study. (Pubmed Central) - Apr 26, 2024
Further, a dose dependent inhibition of cancer cell migration was noted along with apoptosis induction in these cells with levoleucovorin treatment.Communicated by Ramaswamy H. Sarma. The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population.
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: KEYNOTE 975: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) (clinicaltrials.gov) - Apr 17, 2024
P3, N=700, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population. Recruiting --> Active, not recruiting
- | leucovorin calcium / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Apr 17, 2024
P2, N=56, Active, not recruiting, Sponsor: Southwest Autism Research & Resource Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=134 --> 56 | Trial primary completion date: Jan 2025 --> Apr 2024
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: NuTide:302: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (clinicaltrials.gov) - Apr 3, 2024
P1/2, N=107, Completed, Sponsor: NuCana plc
Recruiting --> Active, not recruiting | N=134 --> 56 | Trial primary completion date: Jan 2025 --> Apr 2024 Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Enrollment closed, Combination therapy, Metastases: NuTide:323: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) - Apr 3, 2024
P2, N=182, Active, not recruiting, Sponsor: NuCana plc
Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024 Recruiting --> Active, not recruiting
- ||| Lytgobi (futibatinib) / Otsuka
Enrollment change: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov) - Mar 2, 2024
P2, N=66, Recruiting, Sponsor: Taiho Oncology, Inc.
Recruiting --> Active, not recruiting N=26 --> 66
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial completion date, Trial primary completion date, Combination therapy, Metastases: NuTide:323: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) - Feb 23, 2024
P2, N=171, Recruiting, Sponsor: NuCana plc
N=26 --> 66 Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Sep 2024
- || Avastin (bevacizumab) / Roche
Trial completion: CLIMB: Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab (clinicaltrials.gov) - Jan 31, 2024
P2, N=20, Completed, Sponsor: Asan Medical Center
Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Sep 2024 Active, not recruiting --> Completed
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Jan 26, 2024
P2, N=41, Not yet recruiting, Sponsor: Institut de Recherches Internationales Servier
- ||| NP137 / NETRIS Pharma
Enrollment open, Trial completion date, Metastases: LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Dec 18, 2023
P1, N=52, Recruiting, Sponsor: University Hospital, Grenoble
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Nov 2025
- Tevimbra (tislelizumab) / BeiGene
Tislelizumab combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Preliminary results of a single-arm, open-label phase I/II trial (SYLT-023). (Poster Bd # F11) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_215;
P1/2
A phase II study at the RP2D is ongoing. Clinical trial information: NCT05319639.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204). (Poster Bd # N3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_121;
JCOG2204 is a multi-center, randomized phase II trial comparing neoadjuvant chemotherapy with FLOT (5-fluorouracil/levofolinate/oxaliplatin/docetaxel) versus DOS for resectable type 4 and large type 3 GC...Enrollment in JCOG2204 begun on 14th July, 2023 and clinical trial information is available in Japan Registry of Clinical Trials (jRCTs031230231). Clinical trial information: jRCTs031230231.
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial completion date, Trial primary completion date: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Dec 5, 2023
P=N/A, N=757, Active, not recruiting, Sponsor: Takeda
Clinical trial information: jRCTs031230231. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- | Avastin (bevacizumab) / Roche, Kaitanni (cadonilimab) / Akesobio
Enrollment open, Trial initiation date, Combination therapy, Metastases: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Nov 15, 2023
P2, N=20, Recruiting, Sponsor: Fujian Cancer Hospital
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Nov 2023
- | Cyramza (ramucirumab) / Eli Lilly
Journal, Metastases: Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16. (Pubmed Central) - Oct 30, 2023
Our study demonstrated prospectively that RAM plus FOLFIRI is an effective second-line treatment after anti-EGFR antibody-containing first-line therapy in RAS wild-type and left-sided mCRC. Furthermore, the results were similar for patients who were previously treated with triplet regimen.
- | leucovorin calcium / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Oct 25, 2023
P2, N=134, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Furthermore, the results were similar for patients who were previously treated with triplet regimen. Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025
- | leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) - Oct 25, 2023
P2, N=80, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025 Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
- | leucovorin calcium / Generic mfg.
Enrollment open: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov) - Oct 25, 2023
P2, N=80, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025 Active, not recruiting --> Recruiting
- | Journal: Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy. (Pubmed Central) - Oct 23, 2023
This is the first report that posterior reversible encephalopathy syndrome is caused by a thrombocytopenia regimen, and our case highlights the pathogenic role of a thrombocytopenia regimen in posterior reversible encephalopathy syndrome. However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study.
- ||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, Combination therapy, Metastases: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) (clinicaltrials.gov) - Oct 19, 2023
P3, N=335, Completed, Sponsor: Merck Sharp & Dohme LLC
However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study. Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2023
- | Tevimbra (tislelizumab-jsgr) / BeiGene
Phase classification: SYLT-023: Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab (clinicaltrials.gov) - Sep 18, 2023
P1/2, N=20, Recruiting, Sponsor: Fujian Cancer Hospital
Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2023 Phase classification: P1 --> P1/2
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. (Pubmed Central) - Aug 30, 2023
In 17 cases, the departments for the preparation of cytostatics in the Czech Republic had to accept restrictions on administering the full dose of leucovorin. These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches.
- || Lytgobi (futibatinib) / Otsuka
Enrollment open: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov) - Aug 8, 2023
P2, N=26, Recruiting, Sponsor: Taiho Oncology, Inc.
These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches. Not yet recruiting --> Recruiting
- || Lytgobi (futibatinib) / Otsuka
New P2 trial: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov) - Jul 14, 2023
P2, N=26, Not yet recruiting, Sponsor: Taiho Oncology, Inc.